WEILI HOLDINGS (02372) announced its interim results, with a shareholder loss of 14.4 million yuan, a year-on-year shift from profit to loss.
Waili Holdings (02372) announced its results for the six months ending June 30, 2026. During this period, the group achieved revenue of 65.6 million RMB, an increase of 43.2% year-on-year; the loss attributable to shareholders was 14.4 million RMB, a reversal from profit to loss compared to the previous year; basic loss per share was 1.8 cents.
WEILI HOLDINGS (02372) announced its performance for the six months ending June 30, 2026. During this period, the group achieved revenue of 65.6 million RMB, an increase of 43.2% compared to the same period last year; the loss attributable to shareholders was 14.4 million RMB, a loss compared to a profit in the same period last year; the basic loss per share was 1.8 cents.
Related Articles
CHINARES PHARMA (03320): China Resources Sanjiu Medical & Pharmaceutical's net profit attributable to the parent company for the first half of the year is approximately 1.671 billion yuan, a year-on-year decrease of 7.96%.
CHINARES PHARMA (03320): KPC Pharmaceuticals, Inc. reported a net loss attributable to shareholders of 364 million yuan in the first half of the year, turning from profit to loss compared to the same period last year.
WING TAI PPT (00369) will distribute an interim dividend of HKD 0.03 per share on October 6.
CHINARES PHARMA (03320): China Resources Sanjiu Medical & Pharmaceutical's net profit attributable to the parent company for the first half of the year is approximately 1.671 billion yuan, a year-on-year decrease of 7.96%.
CHINARES PHARMA (03320): KPC Pharmaceuticals, Inc. reported a net loss attributable to shareholders of 364 million yuan in the first half of the year, turning from profit to loss compared to the same period last year.
WING TAI PPT (00369) will distribute an interim dividend of HKD 0.03 per share on October 6.
RECOMMEND
